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ABSTRACT
The present study was conducted on six male buffalo calves to investigate the pharmacokinetics of 
levofl oxacin following a single subcutaneous administration at the dose rate of 3 mg.kg-1 body weight. 
Appreciable plasma concentration of levofl oxacin (0.28 ± 0.01 μg.mL-1) was detected 2.5 min after injection 
and the peak plasma level of 2.94 ± 0.07 μg.mL-1 was observed at 1 h. Drug levels of 0.28 ± 0.01 μg.mL-1 in 
plasma were detected up to 12 h from administration. Rapid absorption of the drug was also evident by the 
high value of the absorption rate constant (2.53 ± 0.53 h-1). The absolute bioavailability of levofl oxacin after 
subcutaneous administration calculated on the basis of AUC (10.5 ± 0.11 μg.mL-1.h) and Ke (0.272 ± 0.009 h-1) 
after a single intravenous injection in buffalo calves was 44.3 ± 1.76 per cent. The high value of AUC (8.02 ± 
0.2 μg.mL-1.h) refl ected major exposure in the buffalo calves. Extensive distribution of the drug into various 
body fl uids and tissues was refl ected by the high value of Vdarea (1.06 ± 0.04 L.kg
-1). The elimination half-life 
and MRT were 4.43 ± 0.1 h and 6.71 ± 0.17 h, respectively. On the basis of the pharmacokinetic parameters, the 
calculated subcutaneous dosage regimen for levofl oxacin in buffalo calves was 4.6 mg.kg-1 at 24 h intervals.
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Introduction 
Fluoroquinolone resistance relates directly to human and veterinary usage and 
emerging bacterial resistance poses the single greatest threat to the future survival of 
fl uoroquinolone drugs as an antibiotic class (BAKKEN, 2004). Levofl oxacin [(-) -9-
Fluoro-3-methyl-10-(4-methyl-1-piprazinyl)-7-oxo-2, 3-dihydro-7H-pyrido [1, 2, 3-de] 
[1, 4]-benzoxazine-6-carboxylic acid], a second generation fl uoroquinolone, possesses 
excellent activity against gram-positive, gram-negative and anaerobic bacteria (DAVIS 
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and BRYSON, 1994; NORTH et al., 1998). As compared to other fl uoroquinolones, ofl oxacin 
and ciprofl oxacin, it also has more pronounced bactericidal activity against organisms 
such as Pseudomonas, Enterobacteriaceae and Klebsiella (KLESEL et al., 1995). The drug 
distributes well to target body tissues and fl uids in the respiratory tract, skin, urine and 
prostrate and its uptake by cells makes it suitable for use against intracellular pathogens 
(LANGTRY and LAMB, 1998). Levofl oxacin is metabolized in the liver to demethyl-
levofl oxacin and levofl oxacin-N-oxide and excreted in urine (LANGTRY and LAMB, 1998). 
The pharmacokinetics of levofl oxacin have been investigated in man (CHULAVATNATOL 
et al., 1999), calves (DUMKA and SRIVASTAVA, 2006, 2007a, and 2007b; DUMKA, 2007; 
DUMKA et al., 2008) and guinea pigs (EDELSTEIN et al., 1996). However, there is only 
meager information available on the pharmacokinetics of levofl oxacin in buffalo species, 
except one report after intramuscular administration of levofl oxacin in buffalo calves 
(RAM et al., 2008). In view of the marked species variation in the pharmacokinetic data of 
antimicrobial drugs, the present study was undertaken to determine the pharmacokinetics 
and an appropriate dosage regimen of levofl oxacin following its single subcutaneous 
administration in buffalo calves. 
Materials and methods 
Experimental animals and drug administration. Six healthy male buffalo calves of 
non-descript breed, ranging between 1-1.5 years of age and 82-128 kg body weight were 
used for the study. The animals were maintained on seasonal green fodder, wheat straw 
and water ad libitum. The average day temperature in the shed was about 25 0C during 
the experimental period. The experimental protocol followed the ethical guidelines on 
the proper care and use of animals. Levofl oxacin [Tavanic (0.5% Levofl oxacin), Hoechst 
Marion Roussel Ltd., India] was administered subcutaneously at the dose rate of 3 mg.kg-
1 body weight into the neck region. 
Collection of samples. Blood samples (5 mL) were withdrawn from the jugular vein 
into heparinized glass centrifuge tubes before and at 1, 2.5, 5, 10, 15, 30 min and 1, 2, 
4, 6, 8, 10, 12, 16 and 24 h after administration of the drug. Plasma was separated by 
centrifugation at 1300 g for 15 min at room temperature and kept at -20 0C until analysis, 
which was usually done on the next day after collection. 
Estimation of drug. The level of levofl oxacin in the plasma samples was estimated 
by a microbiological assay technique (ARRET et al., 1971) using Escherichia coli [ATCC 
(American type culture collection) 10536] as the test organism. This method estimated the 
level of drug and its active metabolites with antibacterial activity. The assay could detect 
a minimum of 0.1 μg.mL-1 of levofl oxacin. For each sample, 9 replicates were analysed 
and compared with the zone of inhibition of the reference solution of levofl oxacin (0.3 
μg.mL-1). The level of levofl oxacin in the samples was calculated as μg.mL-1 of plasma.
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Pharmacokinetic variables and dosage regimen. The plasma concentration-time 
profi le of levofl oxacin after subcutaneous administration in each animal was used 
to establish various pharmacokinetic determinants and mean kinetic variables were 
obtained by averaging the variables calculated for individual animals. Absolute systemic 
bioavailability was calculated by using the values of AUC and β obtained after single 
intravenous administration of levofl oxacin in the same animals used for subcutaneous 
study of levofl oxacin at an interval of 30 days. Pharmacokinetic parameters were 
calculated manually by the computed least-squares linear regression technique (GIBALDI 
and PERRIER, 1982). The maintenance (D’) dose of levofl oxacin was calculated according 
to the equation: D’= Cp(min)
∝.Vd (eβτ-1), where, Cp (min) ∝ is the minimum inhibitory 
concentration of levofl oxacin, β is the elimination rate constant and τ is the dosing interval. 
The priming dose was obtained by omitting -1 from the above equation (BAGGOT, 
1977).
Results 
The plasma levels of levofl oxacin at different time intervals following its single 
subcutaneous injection at the dose rate of 3 mg.kg-1 body weight in buffalo calves 
are presented in Table 1. Subcutaneous injection resulted in an appreciable plasma 
concentration of drug (0.28 ± 0.01 μg.mL-1) at 2.5 min and peak plasma level of 2.94 
± 0.07 μg.mL-1 was attained 1 h post administration. The plasma levels then declined 
gradually to 0.28 ± 0.01 μg.mL-1 at 12 h. 
Table 1. Plasma levels of levofl oxacin in buffalo calves (n = 6) following single subcutaneous 





Mean ± SE1 2 3 4 5 6
2.5 min 0.30 0.28 0.25 0.27 0.29 0.28 0.28 ± 0.01
5 min 0.31 0.29 0.28 0.29 0.32 0.31 0.30 ± 0.01
10 min 0.57 0.60 0.56 0.55 0.57 0.60 0.57 ± 0.01
15 min 1.34 1.46 1.60 1.36 1.40 1.46 1.44 ± 0.04
30 min 2.01 2.05 2.30 2.14 2.10 1.96 2.10 ± 0.05
1 h 2.80 2.80 3.20 3.10 2.90 2.86 2.94 ± 0.07
2 h 2.40 2.00 2.25 2.40 2.30 1.96 2.22 ± 0.08
4 h 1.10 1.30 1.20 1.10 1.10 1.20 1.17 ± 0.03
6 h 0.92 0.86 0.84 0.86 0.88 0.86 0.87 ± 0.01
8 h 0.61 0.56 0.59 0.57 0.57 0.60 0.58 ± 0.01
10 h 0.56 0.46 0.44 0.41 0.35 0.57 0.46 ± 0.03
12 h 0.30 0.29 0.29 0.26 0.27 0.29 0.28 ± 0.01
Values are expressed as μg. mL-1 of plasma 
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Table 2. Pharmacokinetic parameters of levofl oxacin in buffalo calves (n = 6) following a single 
subcutaneous dose of 3 mg.kg-1 body weight
Parameter Unit Mean ± SE
A’ μg.mL-1 0.94 ± 0.13
Ka h-1 2.53 ± 0.53
t½Ka h 0.34 ± 0.07
B μg.mL-1 1.33 ± 0.05
Ke h-1 0.16 ± 0.04
t1/2Ke h 4.43 ± 0.10
AUC μg.mL-1.h 8.02 ± 0.20
AUMC μg. mL-1.h2 53.8 ± 1.61
Vd(area) L.kg
-1 1.06 ± 0.04
MRT h 6.71 ± 0.17
td h 21.4 ± 0.47
Cmax μg.mL
-1 2.94 ± 0.07
tmax min 60.0 ± 0.0
F % 44.3 ± 1.76
A′ and B = zero-time plasma drug concentration intercepts of the regression lines of absorption and elimination 
phases, respectively; Ka and Ke = absorption and elimination rate constants, respectively; t½Ka = absorption 
half-life; t½Ke = elimination half-life; AUC = area under the plasma concentration-time curve; AUMC = area 
under the fi rst moment curve; Vdarea = apparent volume of distribution; MRT = mean residence time; td = 
duration of therapeutic effect; Cmax and tmax = peak plasma drug concentration and time required to attain the 
peak concentration, respectively; F = overall systemic bioavailability.
Evaluation of the results revealed that the disposition pattern of levofl oxacin best 
fi tted the one-compartment open model and it was adequately described by the equation: 
Cp = Be
-βt- A’e-Katwhere, Cp is the plasma level of levofl oxacin at time t and e represents 
the base of natural logarithm, A’ and B are the extrapolated zero-time intercepts of 
the absorption and elimination phases, respectively, Ka and Ke are the absorption and 
elimination rate constants, respectively. Table 2 shows the pharmacokinetic parameters 
that describe the absorption and elimination pattern of levofl oxacin in buffalo calves. 
Taking various dosage intervals, the different desired plasma concentrations ranging from 
0.06 to 0.14 μg.mL-1 and using the values for Ke and Vdarea from Table 2, the required 
doses of levofl oxacin were calculated and are presented in Table 3. 
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Table 3. Calculated subcutaneous dosage regimen of levofl oxacin (mg.kg-1) at various intervals 
for different MICs in buffalo calves 
MIC (μg.mL-1) Dose
Dosage interval (h)
8 12 16 24
0.06 D 0.22 0.42 0.79 2.79
D’ 0.16 0.35 0.72 2.73
0.08 D 0.30 0.56 1.05 3.72
D’ 0.21 0.47 0.97 3.64
0.1 D 037 0.70 1.31 4.65
D’ 0.27 0.59 1.21 4.54
0.12 D 0.45 0.84 1.58 5.58
D’ 0.31 0.71 1.45 5.45
0.14 D 0.52 0.98 1.84 6.51
D’ 0.32 0.83 1.69 6.36
D = priming dose, D’ = maintenance dose
Discussion 
The rapid appearance of levofl oxacin in plasma following its subcutaneous 
administration in buffalo calves suggested that the drug rapidly entered systemic 
circulation. The high value of the absorption rate constant further confi rmed the rapid 
absorption of levofl oxacin. Rapid absorption has also been reported after intramuscular 
injection of levofl oxacin in buffalo calves (RAM et al., 2008), and cross bred calves 
(DUMKA and SRIVASTAVA, 2006) and marbofl oxacin (SCHNEIDER et al., 2004; SHEM-
TOV et al., 1997) in cattle and following extravascular administration of gatifl oxacin in 
buffalo calves (RAIPURIA et al., 2006, 2007). An average plasma concentration of 0.008-
0.125 μg.mL-1 has been reported to be the minimum inhibitory concentration (MIC) of 
levofl oxacin against most gram-positive, gram-negative and atypical bacteria including 
Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus spp., Corynebacterium 
spp., Bacillus spp., Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, 
Proteus mirabilis, Proteus vulgaris, Providencia rettgeri, Enterococcus faecalis, and 
Haemophilus infl uenzae in humans and animal models of infection (DRAGO et al., 2001; 
HO et al., 2004; GRIFFITH et al., 2006; DUGGIRALA et al., 2007). Keeping in mind the 
synergistic effect of the body immune system and other in vivo factors, and to cover most 
of the susceptible organisms, in this discussion, the MIC90 of 0.1 μg.mL
-1 of levofl oxacin 
has been taken into consideration. Drug levels of 0.28 ± 0.01 μg.mL-1 in the plasma were 
detected up to 12 h after administration. Similar to the present fi ndings, peak plasma 
concentrations of 2.8-3.07 μg.mL-1 after extravascular administration in cross bred calves 
(DUMKA and SRIVASTAVA, 2006, and 2007b), 2.95 μg.mL-1 after intramuscular dosing in 
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buffalo calves (RAM et al., 2008) and 3.4 μg.mL-1 after single intraperitoneal injection in 
pneumonic guinea pigs (EDELSTEIN et al., 1996) have been reported for levofl oxacin. 
However, a lower Cmax of 0.23 μg.mL
-1 was attained after subcutaneous administration of 
danofl oxacin in calves (McKELLAR et al., 1999).
The apparent volume of distribution of 1.06 ± 0.04 L.kg-1 in the present study 
indicated good penetration of levofl oxacin into various body fl uids and tissues after 
subcutaneous injection. Large volumes of distribution for levofl oxacin in calves (1.02 
L.kg-1), gatifl oxacin in buffalo calves (3.2 L.kg-1) and danofl oxacin in goats (1.42 L.kg-1) 
have also been reported (ATEF et al., 2001; DUMKA and SRIVASTAVA, 2006; RAIPURIA et 
al., 2007). The high value of AUC (8.02 ± 0.2 μg.mL-1.h) obtained in the present study 
refl ected the large extent of absorption. These observations are in accordance with the 
similar values of AUC for levofl oxacin in calves (7.66 μg.mL-1.h) and buffalo calves 
(8.81 μg.mL-1.h), marbofl oxacin in cows (7.648 μg.mL-1.h) and gatifl oxacin in buffalo 
calves (10.8 μg.mL-1.h) after intramuscular injection (SCHNEIDER et al., 2004; DUMKA 
and SRIVASTAVA, 2006; RAIPURIA et al., 2006; RAM et al., 2008). 
The elimination half-life (4.43 ± 0.1 h) in the present study was comparable to 
the t½β of 4.41 h for danofl oxacin in goats (ALIABADI and LEES, 2001), however it was 
lower than the t½β of 7.06 h for gatifl oxacin in buffalo calves following subcutaneous 
administration (RAIPURIA et al., 2007) and greater than the corresponding values of 3.67 h 
for levofl oxacin (DUMKA and SRIVASTAVA, 2006), 2.53 h for marbofl oxacin (SCHNEIDER 
et al., 2004) and 2.4 h for norfl oxacin (GIPS and SOBACK, 1996) in cattle observed after 
intramuscular administration. 
Among the various pharmacokinetic parameters, bioavailability plays an important 
role in the therapeutic effi cacy of a drug. On the basis of AUC and β after single intravenous 
(10.5 ± 0.11 μg.mL-1.h and 0.272 ± 0.009 h-1, respectively) and subcutaneous administration 
(Table 2) in buffalo calves, the absolute systemic bioavailability of levofl oxacin was 
calculated to be 44.3 ± 1.76 per cent. This fi nding was less than the systemic bioavailability 
of levofl oxacin (56.6%), norfl oxacin (73%) and danofl oxacin (91%) in cattle (APLEY and 
UPSON, 1993; GIPS and SOBACK, 1996; DUMKA and SRIVASTAVA, 2006) and levofl oxacin 
(68.1%) and gatifl oxacin (79.7% and 89.1%) in buffalo calves (RAIPURIA et al., 2006, and 
2007; RAM et al., 2008) reported after their extravascular administration.
On the basis of the present study, the priming and maintenance doses of levofl oxacin, 
at a convenient dosage interval of 24 h, were calculated to be 4.65 and 4.54 mg.kg-1, 
respectively, or under fi eld conditions, for most bacteria sensitive to levofl oxacin, the 
subcutaneous dosage regimen for levofl oxacin, would be 4.6 mg. kg-1 at 24 h intervals for 
bacterial infections in buffalo calves. This dosage was less than the intramuscular dose 
of 1.7 mg.kg-1 at 12 h intervals suggested for levofl oxacin in buffalo calves, considered 
on the basis of a similar dosing interval (RAM et al., 2008). Lack of local reaction or any 
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other adverse effect, rapid absorption, moderate bioavailability and the large volume of 
distribution of levofl oxacin observed in the present study revealed that levofl oxacin may 
be effectively employed by the subcutaneous route in the treatment of bacterial infections 
in buffalo calves. However, in order to establish the dosage of levofl oxacin in buffalo 
calves, further studies are required.
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SAŽETAK
Farmakokinetika levofl oksacina nakon njegove jednokratne supkutane primjene u dozi od 3 mg.kg-1 tjelesne 
mase određivana je na šest muške bivolje teladi. Mjerljiva koncentracija levofl oksacina u plazmi (0,28 ± 0,01 
μg.mL-1) bila je ustanovljena 2,5 minute nakon primjene, a vršna razina od 2,94 ± 0,07 μg.mL-1 ustanovljena 
je jedan sat nakon primjene. Razina lijeka od 0,28 ± 0,01 μg.mL-1 bila je u plazmi dokazana do 12 sati nakon 
primjene. Brza apsorpcija lijeka očitovala se u visokoj vrijednosti stupnja apsorpcije (2,53 ± 0,53 h-1). Apsolutna 
biološka raspoloživost levofl oksacina nakon supkutane primjene izračunana na osnovi AUC (10,5 ± 0,11 μg.mL-
1.h) i Ke (0,272 ± 0,009 h-1) nakon jednokratne intravenske primjene iznosila je 44,3 ± 1,76%. Visoka vrijednost 
AUC (8,02 ± 0,2 μg.mL-1.h) bila je posljedica velike količine primijenjenoga lijeka. Široka raspodjela lijeka u 
različitim tjelesnim tekućinama i tkivima očitovala se velikom vrijednošću Vdarea (1,06 ± 0,04 L.kg
-1). Poluživot 
izlučivanja lijeka iznosio je 4,43 ± 0,1 h, a MRT 6,71 ± 0,17 h. Na osnovi farmakokinetičkih pokazatelja, 
izračunana supkutana doza levofloksanica u bivolje teladi iznosila je 4,6 mg.kg-1 u razmacima od 24 
sata.
Ključne riječi: bivol, telad, levofl oksacin, doziranje, farmakokinetika
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